Afficher la couverture 'Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients | Chevallier, Patrice' en grand format
/5

0 avis

Effectiveness of a third dose of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine over a 6‐month follow‐up period in allogenic hematopoietic stem cells recipients

Archive ouverte

Chevallier, Patrice | Jullien, Maxime | Peterlin, Pierre | Garnier, Alice | Le Bourgeois, Amandine | Coste-Burel, Marianne | Béné, Marie | Guillaume, Thierry

Edité par CCSD ; Wiley -

International audience. This study reports the effectiveness of three injections of BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccine in 141 Allo‐HSCT recipients with a median follow‐up of 6 months post‐third shot. We demonstrate a long‐term high protection of Allo‐HSCT recipients since only 2 infections and one death related to COVID‐19 occurred.

Consulter en ligne

Suggestions

Du même auteur

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine

Archive ouverte | Clémenceau, Béatrice | CCSD

International audience. Background: At variance to humoral responses, cellular immunity after anti-SARS-CoV-2 vaccines has been poorly explored in recipients of allogeneic hematopoietic stem-cell transplantation (Al...

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

Archive ouverte | Jullien, Maxime | CCSD

International audience. Little is known about the immune response to SARS-CoV-2 vaccination in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, several studies have reported tha...

SARS-CoV-2 T-cell responses after one or two COVID-19 vaccine boosters in allogeneic transplant recipients

Archive ouverte | Clémenceau, Béatrice | CCSD

International audience

Chargement des enrichissements...